Heidi Overton appeared before the Senate health committee Thursday as nominee for FDA commissioner, and she spent her hearing dancing around the question of mifepristone, the key abortion medication.
Senators pressed Overton on whether she would protect the drug, and she answered without committing. Anti-abortion groups are pushing to strip mifepristone of its approval entirely, and her answers suggested she is listening more closely to them than to the science.
Overton’s Dodges at the Hearing
Overton was asked direct questions about mifepristone, and she answered them without addressing the substance of the requests. She was asked about her views on the drug, and she danced around the issue.
The stakes are high. Mifepristone is used by millions of Americans, and it is standard care worldwide. Its approval is under attack from several directions, and the FDA’s response could determine whether women can get it.
The American College of Obstetricians and Gynecologists recommends mifepristone for early pregnancy loss, but the FDA has never added miscarriage management to the drug’s label. Overton did not address that gap during her testimony.
Why Mifepristone Matters
Over 7.5 million Americans have used mifepristone paired with misoprostol, the combination that terminates an early pregnancy. That number is a measure of how common the drug has become, and it also shows how deeply its use has settled into routine practice.
The comparison to other medications is stark. Birth control pills went over-the-counter in 2023, and emergency contraception has long sat on drugstore shelves. Neither faces the kind of legal pressure that mifepristone now does.
An estimated 458 deaths are linked to acetaminophen each year, sold freely at stores. The contrast between mifepristone and acetaminophen is telling: one is a target of legal action, and the other is not.
| Medication | Status | Approval Use |
|---|---|---|
| Mifepristone | Under attack | Termination of early pregnancy |
| Misoprostol | Standard care | Paired with mifepristone |
| Birth control pills | OTC since 2023 | Birth control |
| Emergency contraception | On drugstore shelves | Emergency contraception |
| Acetaminophen | Sold freely | Pain relief |
The Legal Fight Around Mifepristone
The Supreme Court threw out a nationwide challenge to mifepristone in FDA v. Alliance for Hippocratic Medicine in 2024. That decision ended the nationwide challenge, but it did not settle the broader fight.
Louisiana filed a separate suit to stop remote prescribing and end telemedicine nationwide. The 5th Circuit issued an order that briefly reinstated in-person dispensing nationwide this spring, but the Supreme Court paused that order to preserve access while the case continues.
The current state of play is that mifepristone remains available, but the legal battles continue. Louisiana is back at the 5th Circuit seeking the same restrictions again, and the FDA’s review of mifepristone is scheduled to finish after the midterms.
Overton acknowledged the FDA’s internal research safety study of mifepristone would “immediately be on her desk” and said she is eager to respond to Louisiana’s litigation. Those commitments are important, but they are also vague.
Who Is Pushing to Strip Mifepristone
Anti-abortion groups celebrated Overton’s nomination as a chance to remove access to mifepristone. The head of Americans United for Life said he spoke with Overton five or six times and predicted she would “expose this drug.”
The prediction is a warning to the FDA, not a compliment. If Overton exposes the drug, the implication is that she will find something wrong with it. The question is whether she will expose the science or expose the political pressure.
The FDA has faced repeated court challenges from abortion opponents over mifepristone. The agency has defended the drug before, but the current administration has shown a willingness to let those fights play out. The FDA’s review of mifepristone is scheduled to finish after the midterms, and Overton’s role in that process will be closely watched.
The State of the FDA
The FDA has fired more than 3,000 staff in the past year. The last commissioner resigned after clashing with the White House. Overton arrives into an agency weakened by turnover and facing ongoing political pressure.
Sen. Maggie Hassan (D-N.H.) asked Overton to name one thing she thought the president had ever been wrong about, and received no answer. Overton’s inability to prioritize science over the White House’s political agenda was so obvious that Hassan outright asked her to name one thing she thought the president had ever been wrong about.
The FDA’s internal research safety study of mifepristone will be on Overton’s desk immediately. She has said she is eager to respond to Louisiana’s litigation. Those commitments are important, but they are also vague.
Where the paper stands
The paper backs medical use of mifepristone and is against blocking patients from it, while taking no side on the broader political fight over the drug’s approval. The hearing showed Overton dodging senators’ questions rather than defending the science behind the medication, and that pattern matches the wider political pressure on the FDA.
The paper’s position on abortion is narrow: it supports medical use and opposes blocking patients from it, but it takes no side on the broader political fight over the drug’s approval. The hearing showed Overton dodging senators’ questions rather than defending the science behind the medication, and that pattern matches the wider political pressure on the FDA.
The FDA’s review of mifepristone is scheduled to finish after the midterms, and Overton’s role in that process will be closely watched. The paper wants the FDA to protect patients and uphold science, but Overton’s first moves have raised doubts about whether she will stand with the science or with the anti-abortion movement.
Key Facts Box
- 7.5 million+ Americans have used mifepristone paired with misoprostol
- 458 deaths linked to acetaminophen each year
- 2023 birth control pills went over-the-counter
- 2024 Supreme Court threw out nationwide challenge in FDA v. Alliance for Hippocratic Medicine
- After midterms FDA’s review of mifepristone is scheduled to finish
- 3,000+ FDA staff fired in the past year
- 5th Circuit order briefly reinstated in-person dispensing this spring
- 5th Circuit hearing Louisiana’s request for the same restrictions again
The FDA has a duty to protect patients and uphold science. Overton has a chance to honor that duty, but she has shown no sign so far that she will. The hearing was a test, and she failed it.
The fight over mifepristone is not going away. Overton is now in position to shape it, and her first moves have raised doubts about whether she will stand with the science or with the anti-abortion movement.
Source material: “Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug,” STAT.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.